T-cell leukemia homeobox protein 1 (TLX1)

T-cell leukemia homeobox protein 1 (TLX1) is a nuclear transcription factor of the NK-like (NKL) homeobox gene family, essential for normal embryonic spleen development and neuronal cell fate specification[1][4][5]. Ectopic expression of TLX1, frequently due to chromosomal translocations, is a critical pathogenic driver in a subset of T-cell acute lymphoblastic leukemias (T-ALL), where it causes developmental arrest of thymocytes and alters oncogene and tumor suppressor gene networks[1][3][5]. TLX1 acts via sequence-specific DNA binding, regulates both protein-coding and non-coding (notably long non-coding RNA) gene networks, and plays a dual role as both transcriptional activator and repressor. While there are not yet approved drugs that directly target TLX1, ongoing research explores targeting downstream effectors such as TLX1-regulated lncRNAs or associated epigenetic regulators[3]. TLX1 expression and its controlled loci are important biomarkers in hematologic malignancy molecular subtyping, but therapeutic modulation is complex due to vital roles in development and homeostasis[1][3][5].

Other names

HOX11TCL3Homeobox protein Hox-11Proto-oncogene TCL-3T-cell leukemia/lymphoma protein 3Homeo box-11 (T-cell leukemia-3 associated breakpoint, homologous to Drosophila Notch)homeo box 11 (T-cell lymphoma 3-associated breakpoint)

Inhibition of gene expression driven by TLX1 (either by knockdown, RNA interference, or chromatin-modifying strategies) BET protein inhibition (as indirect strategy impacting super-enhancer driven TLX1 network)